The Meso Foundation Congratulates Dr. Hassan for Prestigious Award

Hassan_WagnerAwardThe Mesothelioma Applied Research Foundation congratulates Dr. Raffit Hassan of the National Cancer Institute (NCI) on receiving the prestigious Wagner Award at this year’s International Mesothelioma Interest Group’s (iMig) meeting.

Raffit Hassan, MD, is an Investigator and Chief of the Solid Tumor Immunotherapy Section in the Laboratory of Molecular Biology at the National Cancer Institute. Dr. Hassan is a medical oncologist whose laboratory and clinical research is focused on developing novel therapies for the treatment of mesothelioma. His work and collaborations have shown that mesothelin, a tumor antigen that was discovered at the NCI, is a useful target for tumor-specific therapy of malignant mesothelioma. His group is presently conducting clinical trials of three different agents targeting mesothelin namely, SS1P, an anti-mesothelin immunotoxin, MORAb-009, a chimeric anti-mesothelin monoclonal antibody, and CRS-207, a mesothelin tumor vaccine.

Dr. Hassan served on the Meso Foundation’s Science Advisory Board for nearly a decade and for three years was the chair of the board. The Meso Foundation is grateful for all of his contributions to the field of mesothelioma.

The Wagner Award is named after J. Christopher Wagner, who was a leader in the field of mesothelioma by making major contributions to the understanding of mesothelioma, its cause and the goals for prevention. Wagner was the first to establish the connection between mesothelioma and asbestos.The Wagner award is presented every two years to an individual who has made major original contributions to the understanding of mesothelioma, either in basic or applied research.

Previous recipients include Drs. Joseph Testa, Stephen Albelda, Brooke Mossman, Harvey Pass, Bruce Robinson, and Marie-Claude Jaurand.

This year’s award was presented to Dr. Hassan by Dr. Steven Mutsaers.

Wednesday Update from iMig Conference

Mary Hesdorffer, NP, the executive director of the Meso Foundation is in attendance at the International Mesothelioma Interest Group (iMig) conference in Cape Town, South Africa. Mary has sent the following photo updates from Wednesday at the conference.

Cocktail Reception

The entertainment at the cocktail reception.

Dario Barbone, PhD

Dario Barbone, PhD, shared that he will be submitting a grant for consideration to the NCI next week. He credits the Meso Foundation’s grant for providing the funding that permitted him to carry out experiments from which the resulting data can be used in applying for larger grants. We will continue to update you on the careers of these young scientists who are the future of mesothelioma research.

Joe Friedberg and Melissa Culligan

Joe Friedberg, MD, and Melissa Culligan, BSN, RN, are in attendance.

Melissa Culligan

Melissa Culligan, BSN, RN, was the only nurse invited to present in the surgical session. Congratulations for a thoughtful presentation.

David Schrump, MD

David Schrump, MD, head of the Thoracic and Gastrointestinal Oncology Branch at the National Cancer Institute, seen during the poster discussion session.

Mary Hesdorffer to Present at iMig Conference This Week

Mary Speaking at 2013 SymposiumMary Hesdorffer, MS, APRN-BC, the executive director of the Meso Foundation, will be presenting at the 12th International Mesothelioma Interest Group (iMig) Conference in Cape Town, South Africa this week. iMig is an international group of scientists and clinicians working to understand, cure, and prevent mesothelioma. iMig presents an important conference that brings together mesothelioma professionals from around the world to discuss the current state of research and advancements in the field.

Mary is chairing a nursing panel and she will give two presentations at the conference. The first presentation, titled “The Voice of the Meso Community in the United States,” will discuss how the Meso Foundation, with the help of community members, advocated for $9.3 million in federal research funding directed to mesothelioma research since 2008. Mary’s second presentation is title “Promoting Entry into Clinical Trials and Improving Access to Specialist Treatment and Care.”

Mary is a nurse practitioner with over 16 years of experience in mesothelioma treatment. She is an expert in clinical trials for mesothelioma and her work has been published in a variety of scientific journals. Mary serves as the executive director of the Mesothelioma Applied Research Foundation.

Common Asian Spice Shows Promise in Slowing Progression of Mesothelioma

SpicesIt has recently been discovered that the use of curcumin appears promising in slowing the progression of mesothelioma. As Medical Xpress reports, “Scientists from Case Western Reserve University and the Georg-Speyer-Haus in Frankfurt, Germany, demonstrate that application of curcumin, a derivative of the spice turmeric, and cancer-inhibiting peptides increase levels of a protein inhibitor known to combat the progression of this cancer. Their findings appeared in the Aug. 14 online edition Clinical Cancer Research.”

Medical Xpress goes on to explain, “The culprit in sparking many cancers, particularly mesothelioma, is the intracellular protein and transcription factor STAT3 (signal transducer and activator of transcription 3). A signal transducer and activator is a pathway for instructing the growth and survival of cells, and a transcription factor is a protein that controls genetic information directing cells how to perform. STAT3 is notorious for sending signals to trigger the onset of human cancers and to fuel their continued growth. The great neutralizer of STAT3 is PIAS3 (protein inhibitor of activated STAT3). PIAS3 possesses the strength to inhibit and block STAT3′s ability to cause cancer.”

As the article continues, the logistics of the study are explained in further detail. “Investigators assessed PIAS3 expression in tissue samples of mesothelioma solid tumors and the protein inhibitor’s subsequent effects on STAT3 activity. Tissue samples came from three different locations in the country, and information logged for each specimen detailed how long the patient lived and the types of mesothelioma they had. Investigators then linked the levels of PIAS3 with STAT3 activity in each sample. Additionally, investigators examined the effects of curcumin and peptides extracted from PIAS3 segments on malignant mesothelioma cells in vitro.”

Medical Xpress spoke with Afshin Dowlati, MD, a professor of medicine at Case Western Reserve University School of Medicine and the director of the Center for Cancer Drug Development at University Hospitals Seidman Cancer Center. Dowlati stated, “In those mesothelioma patients where PIAS3 is low, indeed STAT3 is activated. Mesothelioma patients who have low PIAS3 and high STAT3 have a greater chance of dying early. On the flip side, those patients with a high PIAS3 levels have a 44 percent decreased chance of dying in one year, which is substantial.”

In explaining the findings of the study, Medical Xpress continues, “Investigators also found that curcumin and PIAS3 peptides raised PIAS3 levels, which brought down STAT3 activity and caused mesothelioma cells to die. Their study served as proof of principle about the effectiveness of these two compounds in treating malignant mesothelioma, a first step in moving a treatment toward clinical trials. Additionally, their findings demonstrated that PIAS3 could serve as a predictive marker for managing mesothelioma because the disease’s tumors do not always progress in a consistent, predictable manner, even when tumor stages, grades and clinical presentations appear similar.”

Dowlati further explained the results, stating, “Our findings suggest that PIAS3 expression positively affects survival in mesothelioma patients and that PIAS3 activation could become a therapeutic strategy. Our interest for the future is that we want to find better, more simple ways to increase intracellular levels of PIAS3 for malignant mesothelioma through the use of synthetic PIAS3 peptide or curcumin analogs. We must develop a curcumin analog that is absorbable by the human body. Currently, curcumin ingested as the spice turmeric has practically no absorption within the gut.”

Visit Medical Xpress to read the full article.

October Events: Regional Conference on Mesothelioma in Chicago

Chicago brochure coverThe 2014 Chicago Regional Conference on Malignant Mesothelioma is a one-day event geared to patients and family members, covering a variety of topics related to mesothelioma and presented by local and regional area experts. The conference is a collaborative effort between the Mesothelioma Applied Research Foundation and The University of Chicago Medicine.

The conference is geared towards patients (newly diagnosed or those looking to learn about second-line and beyond treatment options), caregivers, family members, general health practitioners, and anyone wishing to learn more about mesothelioma. Topics of discussion include imaging, genetics, surgery, chemotherapy, novel treatments, stem cells, immunotherapy, and resources for patients and families.

The location of the conference is the Palmer House Hilton at 17 E Monroe Street, Chicago, IL 60603. The event will begin at 9:30am and commence with a cocktail reception at 5pm. The registration cost is $25, and includes breakfast and lunch.

More information and registration is available at curemeso.org/chicago.

The Meso Foundation is also the host of an annual symposium, taking place in March of every year in the Washington, DC area, and another regional conference in Philadelphia in September.